Document is current
Any future updates will be listed below
-
Authors
Chaïbi, Khalil
Picod, Adrien
Boubaya, Marouane
Tubiana, Sarah
Jullien, Vincent
Magreault, Sophie
Placier, Sandrine
Mallet, Jérémie
Louis, Guillaume
Martin-Lefevre, Laurent
Titeca-Beauport, Dimitri
La Combe, Béatrice
Besset, Sébastien
Badie, Julio
Chevrel, Guillaume
Chudeau, Nicolas
Barbar, Saber
Vinsonneau, Christophe
Forel, Jean-Marie
Thevenin, Didier
Lacave, Guillaume
Nseir, Saad
Oziel, Johanna
Mayaux, Julien
Klouche, Kada
Reignier, Jean
Ricard, Jean-Damien
Quenot, Jean-Pierre
Mebazaa, Alexandre
Azibani, Feriel
Dreyfuss, Didier
Gaudry, Stéphane
- License Information
-
More Information
Article History
Received: 24 April 2025
Accepted: 28 April 2025
First Online: 20 May 2025
Declarations
:
: The study protocol, including the biobank collection, was approved by the competent French legal authority (Comité de Protection des Personnes de Sud-Est V) for all participating centers. Patients (or their surrogates) who were included were informed about the study both verbally and with a written document in accordance with French law.
: Not applicable.
: The AKIKI 2 trial was promoted by the Assistance Publique—Hôpitaux de Paris and funded by a grant of the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2016; AOM16278). Circulating DPP3 concentration was measured free of charge by 4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany Plasma proenkephalin A 119-159 concentration was measured free of charge by Sphingotec GmbH, Hennigsdorf, Germany The Cardiovascular Markers in Stress Conditions Research Group is supported by a research grant from 4TEEN4 Pharmaceuticals GmbH, which allowed salary support for A. Picod. A. Mebazaa received fees as a member of advisory board from Sphingotec. The other authors declare no competing interest regarding the submitted work.
